LHNYSEServices-Medical LaboratoriesFiscal year ends December 31
LABCORP HOLDINGS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$318.83+0.88 (+0.28%)
Close on Oct 19, 2026
- Market cap
- $26.14B
- P/E (TTM)
- 26.4
- Dividend yield
- 0.90%
LABCORP HOLDINGS INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | $10.88B | $10.14B | $9.42B | $9.20B | $10.36B | $9.25B | $7.00B | – | – | – | 78.0% | +7.2% |
| Biopharma Laboratory Services | $3.10B | $2.92B | $2.77B | $2.70B | – | – | – | – | – | – | 22.2% | +6.0% |
| Covance Drug Development [Member] | – | – | – | – | – | – | $4.58B | $4.31B | $3.45B | $3.25B | – | – |
| LabCorp Diagnostics [Member] | – | – | – | – | – | – | $7.00B | $7.03B | $6.86B | $6.31B | – | – |
| Drug Development | – | – | $2.77B | $2.70B | $2.86B | $4.88B | $4.58B | – | – | – | – | – |
| Clinical diagnostics laboratory [Member] | – | – | – | – | – | – | – | – | $7.17B | $6.59B | – | – |
| Other Segments [Member] | – | – | – | – | – | – | – | – | $3.04B | $2.84B | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | $1.78B | $1.61B | $1.59B | $2.03B | $3.21B | $2.80B | $1.09B | $1.17B | – | – | +10.8% |
| Biopharma Laboratory Services | $498.50M | $458.90M | $396.30M | $389.10M | – | – | – | – | – | – | +8.6% |
| Corporate Segment [Member] | -$482.20M | -$670.80M | -$644.10M | -$468.80M | -$404.50M | -$299.40M | -$167.30M | -$144.60M | -$140.60M | -$147.90M | -28.1% |
| Covance Drug Development [Member] | – | – | – | – | – | – | $411.50M | $303.60M | $144.90M | $236.50M | – |
| LabCorp Diagnostics [Member] | – | – | – | – | – | – | $1.09B | $1.17B | $1.30B | $1.18B | – |
| Drug Development | – | – | $396.30M | $389.10M | $501.00M | $721.60M | $411.50M | $303.60M | – | – | – |
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | – | – | – | – | $8.98B | $8.84B | $8.23B | $7.64B | – | – |
| Canada | – | – | – | – | – | – | $333.30M | $342.20M | $327.80M | $295.80M | – | – |
| United Kingdom | – | – | – | – | – | – | $507.90M | $438.90M | $302.00M | $275.90M | – | – |
| Switzerland | – | – | – | – | – | – | $532.90M | $527.40M | $484.40M | $450.50M | – | – |
| Other countries [Member] | – | – | – | – | $976.40M | $941.00M | $1.20B | $1.18B | $857.70M | $774.50M | – | – |
| Europe [Member] | – | – | – | – | $2.05B | $1.51B | – | – | – | – | – | – |
| North America | – | – | – | – | $13.09B | $11.53B | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Labcorp's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.